{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:28:04Z","timestamp":1788413284279,"version":"build-2803163510"},"posted":{"date-parts":[[2025,3,7]]},"group-title":"Neurology","reference-count":52,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:00:00Z","timestamp":1741305600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,3,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Inflammation plays a critical role in brain injury following acute ischemic stroke (AIS). Transcutaneous auricular vagus nerve stimulation (taVNS) has shown anti-inflammatory properties in various conditions, but its efficacy in AIS remains unexplored. We investigated if taVNS could mitigate post-AIS inflammation and its safety.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In this randomized, sham-controlled trial with blinded outcomes assessment, patients with anterior circulation large vessel occlusion (LVO) AIS were assigned to twice-daily taVNS or sham stimulation for five days or until discharge. Key inclusion criteria included age \u226518 years, National Institutes of Health Stroke Scale (NIHSS) \u22656, anterior circulation LVO, and enrollment within 36 hours of last known normal. Primary endpoints were changes in inflammatory biomarkers (white blood cells and cytokines including interleukins (IL)-1\u03b2, 6, 10, 17\u03b1, and tumor necrosis factor alpha (TNF\u03b1) measured at baseline and Days 1, 3, 5, and 7, and taVNS safety. Secondary exploratory endpoints included change in NIHSS, 90 day modified Rankin score (mRS), and safety (bradycardia, hypotension, infection, and death).<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Thirty-five patients (17 taVNS, 18 sham) were enrolled. The taVNS group showed a significant rate of change in normalized aggregate pro-inflammatory cytokines and interleukin-6 levels compared to sham (p=0.04 and p&lt;0.001, respectively). Each 1 pg\/mL reduction in interleukin-6 correlated with a 0.798-point improvement in NIHSS in the taVNS group (95% confidence interval [0.077, 1.518], p = 0.031]), with no significant correlation in the sham group. IL-1\u03b2, 10, 17\u03b1, and TNF\u03b1 showed reduction in cytokine levels, but did not reach statistical significance. There were no statistically significant differences amongst mRS and safety outcomes between both groups.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>taVNS safely reduced post-AIS inflammation in anterior circulation LVO stroke patients, demonstrating biological effects. Secondary analyses also found potential effects in NIHSS improvements. These promising findings warrant further investigation in larger trials.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>ClinicalTrials.gov ID<\/jats:title>\n                  <jats:p>\n                    NCT05390580,\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT05390580\">https:\/\/clinicaltrials.gov\/study\/NCT05390580<\/jats:ext-link>\n                  <\/jats:p>\n                <\/jats:sec>","DOI":"10.1101\/2025.03.06.25323500","type":"posted-content","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T19:20:24Z","timestamp":1741375224000},"source":"Crossref","is-referenced-by-count":6,"title":["Transcutaneous Auricular Vagus Nerve Stimulation Reduces Inflammatory Biomarkers and May Improve Outcomes after Large Vessel Occlusion Strokes: Results of the Randomized Clinical Trial NUVISTA"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7724-1772","authenticated-orcid":false,"given":"Osvaldo J.","family":"Laurido-Soto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8785-9499","authenticated-orcid":false,"given":"Gansheng","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan Searles","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8625-4698","authenticated-orcid":false,"given":"Anna L.","family":"Huguenard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara","family":"Donovan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3197-3062","authenticated-orcid":false,"given":"James","family":"Giles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5167-5097","authenticated-orcid":false,"given":"Rajat","family":"Dhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8666-5369","authenticated-orcid":false,"given":"Opeolu","family":"Adeoye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3979-0906","authenticated-orcid":false,"given":"Jin-Moo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Leuthardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2025031920350990000_2025.03.06.25323500v1.1","doi-asserted-by":"crossref","unstructured":"Malhotra K GJ , Saver JL . Ischemic strokes due to large-vessel occlusions contribute disproportionately to stroke-related dependence and death: a review. Fron Neurol. 2017:651. doi:","DOI":"10.3389\/fneur.2017.00651"},{"key":"2025031920350990000_2025.03.06.25323500v1.2","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.119.028891"},{"key":"2025031920350990000_2025.03.06.25323500v1.3","doi-asserted-by":"crossref","unstructured":"Nour M , Scalzo, F. & Liebeskind, D. S. Ischemia-reperfusion injury in stroke. Interv Neurol. 2013:185\u2013199. doi:","DOI":"10.1159\/000353125"},{"key":"2025031920350990000_2025.03.06.25323500v1.4","doi-asserted-by":"crossref","unstructured":"Mizuma A , You, J. S. & Yenari, M. A. Targeting reperfusion injury in the age of mechanical thrombectomy. Stroke. 2018:1796\u20131802. doi:","DOI":"10.1161\/STROKEAHA.117.017286"},{"key":"2025031920350990000_2025.03.06.25323500v1.5","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-019-0221-1"},{"key":"2025031920350990000_2025.03.06.25323500v1.6","doi-asserted-by":"crossref","unstructured":"Ridker PM LT. Anti-inflammatory therapies for cardiovascular disease. Eur Heart J. 2014:1782\u20131791. doi:","DOI":"10.1093\/eurheartj\/ehu203"},{"key":"2025031920350990000_2025.03.06.25323500v1.7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18030496"},{"key":"2025031920350990000_2025.03.06.25323500v1.8","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.00136.2018"},{"key":"2025031920350990000_2025.03.06.25323500v1.9","doi-asserted-by":"crossref","unstructured":"Ramiro L SA , Garc\u00eda-Berrocoso T , Montaner J .. Inflammatory molecules might become both biomarkers and therapeutic targets for stroke management. Therapeutic advances in neurological disorders. 2018. doi:","DOI":"10.1177\/1756286418789340"},{"key":"2025031920350990000_2025.03.06.25323500v1.10","doi-asserted-by":"crossref","unstructured":"Shichita Tet a . Pivotal role of cerebral interleukin17-producing gammadeltaT cells in the delayed phase of ischemic brain injury. Nat Med. 2009:946\u2013950. doi:","DOI":"10.1038\/nm.1999"},{"key":"2025031920350990000_2025.03.06.25323500v1.11","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000003373"},{"key":"2025031920350990000_2025.03.06.25323500v1.12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17040497"},{"key":"2025031920350990000_2025.03.06.25323500v1.13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23010014"},{"key":"2025031920350990000_2025.03.06.25323500v1.14","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/297241"},{"key":"2025031920350990000_2025.03.06.25323500v1.15","doi-asserted-by":"publisher","DOI":"10.1186\/s12950-016-0140-5"},{"key":"2025031920350990000_2025.03.06.25323500v1.16","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.118.023928"},{"key":"2025031920350990000_2025.03.06.25323500v1.17","doi-asserted-by":"publisher","DOI":"10.4137\/CGast.S31779"},{"key":"2025031920350990000_2025.03.06.25323500v1.18","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2018.00798"},{"key":"2025031920350990000_2025.03.06.25323500v1.19","doi-asserted-by":"publisher","DOI":"10.1007\/s12031-018-1227-7"},{"key":"2025031920350990000_2025.03.06.25323500v1.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.brs.2011.01.009"},{"key":"2025031920350990000_2025.03.06.25323500v1.21","doi-asserted-by":"publisher","DOI":"10.1002\/jnr.22812"},{"key":"2025031920350990000_2025.03.06.25323500v1.22","unstructured":"FDA. Summary of safety and effectiveness data (SSED): FDA approval for VNS: Depression, Seizures, and Chronic Stroke Rehabiliation. Accessed 8\/31\/2022."},{"key":"2025031920350990000_2025.03.06.25323500v1.23","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2019.00854"},{"key":"2025031920350990000_2025.03.06.25323500v1.24","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2019.00772"},{"key":"2025031920350990000_2025.03.06.25323500v1.25","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-25864-1"},{"key":"2025031920350990000_2025.03.06.25323500v1.26","doi-asserted-by":"publisher","DOI":"10.3171\/2024.10.Jns241643"},{"key":"2025031920350990000_2025.03.06.25323500v1.27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0301154"},{"key":"2025031920350990000_2025.03.06.25323500v1.28","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c332"},{"key":"2025031920350990000_2025.03.06.25323500v1.29","doi-asserted-by":"publisher","DOI":"10.1111\/jon.13109"},{"key":"2025031920350990000_2025.03.06.25323500v1.30","doi-asserted-by":"publisher","DOI":"10.1007\/s12028-023-01742-0"},{"key":"2025031920350990000_2025.03.06.25323500v1.31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1161067"},{"key":"2025031920350990000_2025.03.06.25323500v1.32","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.9.7.27"},{"key":"2025031920350990000_2025.03.06.25323500v1.33","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2020.00284"},{"key":"2025031920350990000_2025.03.06.25323500v1.34","unstructured":"Commission TJ. Specifications Manual for Joint Commission National Quality Measures. 2017."},{"key":"2025031920350990000_2025.03.06.25323500v1.35","first-page":"49583","article-title":"International Conference on Harmonisation","volume":"63","author":"Food and Drug Administration","year":"1998","journal-title":"Guidance on Statistical Principles for Clinical Trials"},{"key":"2025031920350990000_2025.03.06.25323500v1.36","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-017-0723-4"},{"key":"2025031920350990000_2025.03.06.25323500v1.37","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000137607.61697.77"},{"key":"2025031920350990000_2025.03.06.25323500v1.38","unstructured":"U.S. Food and Drug Administration. Adjusting for Covariates in Randomized Clinical Trials for Drugs and Biological Products Guidance for Industry. 2023"},{"key":"2025031920350990000_2025.03.06.25323500v1.39","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2023.1215757"},{"key":"2025031920350990000_2025.03.06.25323500v1.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.brs.2023.07.050"},{"key":"2025031920350990000_2025.03.06.25323500v1.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2014.07.015"},{"key":"2025031920350990000_2025.03.06.25323500v1.42","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1612930114"},{"key":"2025031920350990000_2025.03.06.25323500v1.43","doi-asserted-by":"crossref","unstructured":"Yilmaz G , Arumugam, T. V. , Stokes, K. Y. & Granger, D. N. Role of T lymphocytes and interferon gamma in ischemic stroke. Circulation. 2006:2105\u20132112. doi:","DOI":"10.1161\/CIRCULATIONAHA.105.593046"},{"key":"2025031920350990000_2025.03.06.25323500v1.44","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.124.047820"},{"key":"2025031920350990000_2025.03.06.25323500v1.45","doi-asserted-by":"publisher","DOI":"10.1038\/nature01339"},{"key":"2025031920350990000_2025.03.06.25323500v1.46","doi-asserted-by":"crossref","unstructured":"Tan G , Huguenard AL , Donovan KM , Demarest P , Liu X , Li Z , Adamek M , Lavine K , Vellimana AK , Kummer TT , et al. The effect of transcutaneous auricular vagus nerve stimulation on cardiovascular function in subarachnoid hemorrhage patients: a safety study. 2024","DOI":"10.7554\/eLife.100088.1"},{"key":"2025031920350990000_2025.03.06.25323500v1.47","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.123.043414"},{"key":"2025031920350990000_2025.03.06.25323500v1.48","unstructured":"Mandalaneni K RA . Vagus Nerve Stimulator. Treasure Island (FL); 2024."},{"key":"2025031920350990000_2025.03.06.25323500v1.49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0301154"},{"key":"2025031920350990000_2025.03.06.25323500v1.50","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.119.028891"},{"key":"2025031920350990000_2025.03.06.25323500v1.51","doi-asserted-by":"publisher","DOI":"10.1111\/jon.13109"},{"key":"2025031920350990000_2025.03.06.25323500v1.52","doi-asserted-by":"publisher","DOI":"10.1007\/s12028-023-01742-0"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2025.03.06.25323500","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T20:30:12Z","timestamp":1768509012000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2025.03.06.25323500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,7]]},"references-count":52,"URL":"https:\/\/doi.org\/10.1101\/2025.03.06.25323500","relation":{},"subject":[],"published":{"date-parts":[[2025,3,7]]},"subtype":"preprint"}}